CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in…
Biotechnology
DE, Tübingen [HQ]
Cash Flow Statements
6 Sheets · Starting from 2023In Million EUR. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Cash Flow (OCF) | -74.00 | -86.00 | 522.00 | -733.00 | -286.00 | -262.00 | |
| Operating Cash (Net) | -74.00 | -86.00 | 522.00 | -733.00 | -286.00 | -262.00 | |
| Accounts Receivable | -5.00 | -10.00 | -32.00 | -19.00 | -16.00 | -7.00 | |
| Accounts Payable | 9.00 | -9.00 | 620.00 | 179.00 | -96.00 | -29.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | |
| Change | -1.00 | -22.00 | 578.00 | -69.00 | -125.00 | -66.00 | |
| Other WC | -5.00 | - - | -1.00 | -1.00 | 35.00 | 17.00 | |
| Investing Activities | |||||||
| Used Cash (Net) | -4.00 | 28.00 | -45.00 | -127.00 | -93.00 | -54.00 | |
| Capital Expenditure | -14.00 | -12.00 | -47.00 | -127.00 | -93.00 | -54.00 | |
| Purchases of Investments | - - | - - | -1.00 | - - | - - | - - | |
| Sale/Maturity of Investment | 10.00 | 38.00 | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | -14.00 | -12.00 | -47.00 | -127.00 | -93.00 | -54.00 | |
| Acquisitions (Net) | - - | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | 2.00 | 3.00 | -3.00 | -5.00 | -2.00 | |
| Financing Activities | |||||||
| Used Cash (Net) | - - | -67.00 | -819.00 | -344.00 | -63.00 | -226.00 | |
| Debt Repayment | - - | -1.00 | -97.00 | -28.00 | -4.00 | -5.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | 438 | - - | - - | |
| Issued | - - | - - | 867.00 | 404.00 | 66.00 | 231.00 | |
| Repurchased | - - | - - | - - | -34.00 | - - | - - | |
| Other Financing Activities | - - | 69.00 | 49.00 | 3.00 | - - | 236.00 | |
| Cash Balances | |||||||
| Begin of Period | 99.00 | 21.00 | 30.00 | 1,322.00 | 811.00 | 494.00 | |
| End of Period | 21.00 | 30.00 | 1,322.00 | 811.00 | 495.00 | 402.00 | |
| Change | -78.00 | 9.00 | 1,291.00 | -511.00 | -315.00 | -91.00 | |
| Non-Cash Balances | |||||||
| Depreciation and Amortization | 3.00 | 7.00 | 10.00 | 15.00 | 23.00 | 26.00 | |
| Stock Based Compensation | - - | 19.00 | 14.00 | 14.00 | 9.00 | 7.00 | |
| Other | -1.00 | 9.00 | 51.00 | -480.00 | 57.00 | 170.00 | |
| Highlighted metrics | |||||||
| Free Cash Flow (FCF) | -88.00 | -99.00 | 475.00 | -861.00 | -379.00 | -316.00 | |
| Cash Conversion Cycle (CCC) | 69.00 | 381.00 | -66.00 | -35.00 | 125.00 | 194.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||
| Forex Effect on Cash | - - | - - | -5.00 | 4.00 | - - | -1.00 |